Covid 19 Research using Clinical Trials (Home Page)
amoxicillin/clavulanateWiki
Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation
Correlated Drug Terms (1)
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug88 | Azithromycin with amoxicillin/clavulanate Wiki | 1.00 |
Correlated HPO Terms (0)
| Name (Synonyms) | Correlation |
|---|
There is one clinical trial.
Clinical Trials
1 Azithromycin With Amoxicillin/Clavulanate Versus Amoxicillin/Clavulanate Alone in COVID-19 Patients With Pneumonia and Hospitalized in a Non-intensive Care Unit Ward (AziA): a Superiority Open-label Randomized Controlled Trial
The global pandemic of novel coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) began in Wuhan, China, in December 2019, and has since spread worldwide.1 As of April 14, 2020, there have been more than 1.5 million reported cases and 124 000 deaths in more than 200 countries. A recent open-label nonrandomized French study reporte that addition of azithromycin to hydroxychloroquine in 6 patients resulted in numerically superior viral clearance (6/6, 100%) compared with hydroxychloroquine monotherapy (8/14, 57%) or control (2/16, 12.5%). Azithromycin alone has never been tested, whereas azithromycin has immunomodulating and anti-inflammatory properties that could theoretically prevent or limit secondary worsening. Our hypothesis is that azithromycin combined with amoxicillin/clavulanate will be superior to amoxicillin/clavulanate alone to obtain viral clearance at Day 6 in COVID-19 patients with pneumonia and hospitalized in a non-intensive care unit ward.
NCT04363060 COVID-19 Pneumonia Combination Product: Azithromycin with amoxicillin/clavulanate Drug: amoxicillin/clavulanate MeSH:Pneumonia
HPO:Pneumonia
Primary Outcomes
Description: Rate of positive SARS-CoV-2 RT-PCR on nasopharyngeal sample
Measure: Rate of positive SARS-CoV-2 RT-PCR Time: Day 6
Secondary Outcomes
Description: Rate of positive SARS-CoV-2 RT-PCR on nasopharyngeal sample
Measure: Rate of positive SARS-CoV-2 RT-PCR Time: Day 10
Description: Clinical evolution on the WHO Ordinal Scale for Clinical Improvement for COVID-19 score. Scale ranging from 0 to 8 (0:unifected; 8:dead)
Measure: Clinical evolution on the World Health Organization Ordinal Scale for Clinical Improvement for COVID-19 Time: day 6, day 10, and day 30
Description: Total duration of antibiotic treatment during the 30 days following inclusion
Measure: Total duration of antibiotic treatment during the 30 days following inclusion Time: 30 days
Description: Number of all-cause mortality during the 30 days following inclusion
Measure: Number of all-cause mortality during the 30 days following inclusion Time: 30 days
Description: Number of in-hospital mortality during the 30 days following inclusion
Measure: Number of in-hospital mortality during the 30 days following inclusion Time: 30 days
Description: Number of patients transferred to intensive care unit during the 30-day follow-up
Measure: Number of patients transferred to intensive care unit during the 30-day follow-up Time: 30 days
Description: Number of days without mechanical ventilation during the 30 days following inclusion
Measure: Number of days without mechanical ventilation during the 30 days following inclusion Time: 30 days
Description: adverse events attributable to antibiotic treatment during the 30 days following inclusion
Measure: adverse events attributable to antibiotic treatment during the 30 days following inclusion Time: 30 days
Description: Hospital length of stay during the 30 days following inclusion
Measure: Hospital length of stay during the 30 days following inclusion Time: 30 days
Related HPO nodes (Using clinical trials)
HP:0002090: Pneumonia
Genes 208
TIMM8A DNAH9 GAS8 DNAH11 TNFRSF11A TBC1D24 SPAG1 MS4A1 GAS2L2 CCDC151 NIPBL BTK LIG4 NFKB2 TCIRG1 IGLL1 RNF168 STAT3 TAF1 RSPH4A CFTR NME8 DNAAF4 LEP CCDC65 NADK2 CD55 COL11A2 NHLRC1 PEPD CFAP300 LTBP3 WAS DNAI1 TBCD IL2RG GFI1 NBN RSPH1 CCDC39 PMM2 ICOS TNFSF12 IFNGR1 CARD11 SFTPC DNAL1 OFD1 ZMYND10 IL21R FMO3 SLC35A1 PLOD1 ORC6 RAG2 CACNA1C GAS8 RYR1 CFAP298 GNPTAB TNFRSF13B KDM6A PANK2 RANBP2 CYBA USB1 UBB DOCK8 ADA DNAAF2 KMT2D SAMD9 MUC5B IL7R DNAAF1 ICOS RAG2 CARD11 PTPRC ALMS1 NOTCH3 NSMCE3 DNAI1 TNFRSF13C GRHL3 EGFR IL2RG DNAAF6 PNP DNAH5 SETBP1 CR2 CD3E ADA MASP2 SFTPA2 ACTA1 RAC1 TTC25 FCGR2A ZAP70 SPEF2 IGHM DNAAF5 NBN CD247 DDR2 CD19 ACADVL KIAA0586 TK2 BLNK ARMC4 SGCG RAG1 CXCR4 NCF1 SRP54 FOXP3 IRF8 CFAP221 RNU4ATAC KCNJ6 LRBA CD3D P4HTM SELENON CCDC114 TNFRSF13B PLG DCLRE1C SLC25A24 DCLRE1C ICOS IL7R FOXJ1 JAK3 IL2RG CASP8 RAG1 OSTM1 CFAP410 CCNO NCF2 UNC119 TNFRSF13C JAK3 RNF125 STK36 POLA1 CD19 CR2 DNAH1 RSPH3 RSPH9 CYBB DRC1 DCLRE1C CCDC103 DNAAF3 LRRC56 PIGN LRRC6 SP110 PRKCD ACP5 CCDC40 SLC35C1 BTK MTHFD1 PGM3 RAG1 TERT CHD7 CFB TGFB1 RNU4ATAC SMARCD2 NKX2-1 OFD1 ZBTB24 BTK DNAI2 WDR19 ZAP70 CD79B CD81 COL11A2 NFIX RAG2 ELANE AFF4 NFKB1 IL2RG TNFRSF13C TNFSF12 CCDC114 ADA GBA DNAJB13 RPGR CSPP1 RMRP EPM2A DNMT3B NFKB2 MCIDAS HYDIN SNP 0
Primary Outcomes
Description: Rate of positive SARS-CoV-2 RT-PCR on nasopharyngeal sample
Measure: Rate of positive SARS-CoV-2 RT-PCR Time: Day 6Secondary Outcomes
Description: Rate of positive SARS-CoV-2 RT-PCR on nasopharyngeal sample
Measure: Rate of positive SARS-CoV-2 RT-PCR Time: Day 10Description: Clinical evolution on the WHO Ordinal Scale for Clinical Improvement for COVID-19 score. Scale ranging from 0 to 8 (0:unifected; 8:dead)
Measure: Clinical evolution on the World Health Organization Ordinal Scale for Clinical Improvement for COVID-19 Time: day 6, day 10, and day 30Description: Total duration of antibiotic treatment during the 30 days following inclusion
Measure: Total duration of antibiotic treatment during the 30 days following inclusion Time: 30 daysDescription: Number of all-cause mortality during the 30 days following inclusion
Measure: Number of all-cause mortality during the 30 days following inclusion Time: 30 daysDescription: Number of in-hospital mortality during the 30 days following inclusion
Measure: Number of in-hospital mortality during the 30 days following inclusion Time: 30 daysDescription: Number of patients transferred to intensive care unit during the 30-day follow-up
Measure: Number of patients transferred to intensive care unit during the 30-day follow-up Time: 30 daysDescription: Number of days without mechanical ventilation during the 30 days following inclusion
Measure: Number of days without mechanical ventilation during the 30 days following inclusion Time: 30 daysDescription: adverse events attributable to antibiotic treatment during the 30 days following inclusion
Measure: adverse events attributable to antibiotic treatment during the 30 days following inclusion Time: 30 daysDescription: Hospital length of stay during the 30 days following inclusion
Measure: Hospital length of stay during the 30 days following inclusion Time: 30 days